Oxaliplatin-Based Chemotherapy
The study's restriction to SOX or CAPEOX limits generalisability to other chemotherapy regimens. The article says adding immune checkpoint inhibitors to chemotherapy has not been shown to increase CINV risk. Eligible trial chemotherapy mus…
1 sources - 4 claims
The study's restriction to SOX or CAPEOX limits generalisability to other chemotherapy regimens. The article says adding immune checkpoint inhibitors to chemotherapy has not been shown to increase CINV risk. Eligible trial chemotherapy must be SOX or CAPEOX, with or without PD-1 or PD-L1 inhibitor immunotherapy. Oxaliplatin-based doublet chemotherapy is widely used for gastric and gastro-oesophageal junction cancer and is moderately emetogenic.